Cardiac Enzymes and Cardiac Peptides as Biomarkers of Cardiovascular Risk Associated With Obesity
Özet
Obesity prevalence is increasing worldwide among children, adolescents and adults. Obesity is classified as a chronic disease and is known to contribute to an increased risk of cardiovascular diseases. Cardiovascular diseases are disorders affecting the heart and blood vessels. They encompasses disorders such as coronary heart disease, heart failure, cerebrovascular disease, stroke, rheumatic heart disease. They constitute leading causes of death. Childhood obesity is associated with cardiovascular diseases, accelerated vascular aging and related risk factors. Deteriorated diastolic function, atrial conduction and heart rate responses were also reported in obese children. The early prediction of cardiovascular disease risk, therefore, gains importance for the prevention of this group of lethal diseases.
The aim of this chapter was to summarize existing novel circulating biomarkers as well as new generation biomarkers in addition to well-known and widely used traditional biomarkers concerning cardiovascular problems. Reports related to the matter in pediatrics field were scarce. The introduction of recent limited number of studies performed on children and adolescents is quite important. The chapter was focused particularly on cardiac enzymes and cardiac peptides. The aim was to guide future studies in pediatric population on cardiac enzymes and peptides commonly studied in adults.
Referanslar
Cardiovascular diseases-World Health Organization (WHO) https://www.who.int>Health topics
Kelly AS, Armstrong SC, Michalsky MP, et al. Obesity in adolescents: A Review. Journal of American Medical Association. 2024;332(9):738-748.
Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Frontiers in Cardiovascular Medicine. 2023;10:1136340.
Burki T. European Commission classifies obesity as a chronic disease. The Lancet. Diabetes & Endocrinology. 2021;9(7):418.
Lava SAG. Cardiovascular disease in children: The future is now. Children (Basel). 2023;10(5):886.
Chung ST, Krenek A, Magge SN. Childhood obesity and cardiovascular disease risk. Current Atherosclerosis Reports. 2023;25(7):405-415.
Lee J, Cha SG, Lee JS, et al. Association between obesity and cardiovascular disease risk factors in different age groups of adolescents: an analysis of data from the Korean national health and nutritional examination survey. Children (Basel). 2023;10(5):827.
Salama M, Balagopal B, Fennoy I, et al. Childhood obesity, diabetes and cardiovascular disease risk. Journal of Clinical Endocrinology and Metabolism. 2023;108(12):3051-3066.
Casagrande SS, Lawrence JM. Cardiovascular disease risk factors and their associations with inflammation among US adolescents: NHANES, 2015 to March 2020. BMJ Open Diabetes Research & Care. 2024;12(4):e004148.
Ryder JR, Northrop E, Rudser KD, et al. Accelerated early vascular aging among adolescents with obesity and/or Type 2 diabetes mellitus. Journal of the American Heart Association. 2020;9(10):e014891.
Kocabaş A, Çağlak E, Turan Ö, et al. Effects of childhood obesity on myocardial performance, autonomic and conduction properties of the heart. Cardiology in the Young. 2024;34(3):513-518.
Mancini GB, Dahlöf B, Díez J. Surrogate markers for cardiovascular disease: structural markers. Circulation. 2004;109(25 Suppl 1):IV22-30.
Cohn JN, Quyyumi AA, Hollenberg NK, et al. Surrogate markers for cardiovascular disease: functional markers. Circulation. 2004;109(25 Suppl 1):IV31-46.
Giglio RV, Stoian AP, Haluzik M, et al. Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochimica et Biophysica Acta. Molecular Basis of Disease. 2021;1867(8):166148.
Wang J, Tan GJ, Han LN, et al. Novel biomarkers for cardiovascular risk prediction. Journal of Geriatric Cardiology : JGC. 2017;14(2):135-150.
Wong Y-K, Tse H-F. Circulating biomarkers for cardiovascular disease risk prediction in patients with cardiovascular disease. Frontiers in Cardiovascular Medicine. 2021;8:713191.
Thupakula S, Nimmala SSR, Ravula H, et al. Emerging biomarkers for the detection of cardiovascular diseases. The Egyptian Heart Journal : (EHJ) : Official Bulletin of the Egyptian Society of Cardiology. 2022;74(1):77.
Albuali W. Predicting factors and outcomes of acute myocarditis in children - a 5-year experience in a teaching hospital from the Eastern province of Saudi Arabia. Journal of Medicine and Life. 2022;15(10):1229-1233.
Fang M, Zhang S, Tang O, et al. Determinants of high-sensitivity cardiac troponin t and ı in us children and adolescents. Journal of the American Heart Association. 2024;13(12):e035142.
Morace C, Curatola SL, Mandraffino G, et al. Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients. Italian Journal of Pediatrics. 2023;49(1):108.
do Prado WL, Josephson S, Cosentino RG, et al. Preliminary evidence of glycine as a biomarker of cardiovascular disease risk in children with obesity. International Journal of Obesity (London). 2023;47(10):1023-1026.
Aakre KM, Meex SJR, Mills NL. Cardiac troponin reporting in children and young adults: time to change clinical practice. Circulation. 2023;148(1):17-19.
Ravà L, Fintini D, Mariani M, et al. High 1-h glucose in youths with obesity as marker of prediabetes and cardiovascular risk. Journal of Endocrinological Investigation. 2023;46(12):2555-2562.
Gearhart A, Esteso P, Sperotto F, et al. Nucleated red blood cells are predictive of in-hospital mortality for pediatric patients. Pediatric Emergency Care. 2023;39(12):907-912.
de Oliveira dos Santos AR, de Oliveira Zanuso B, Miola VFB, et al. Adipokines, myokines, and hepatokines: Crosstalk and metabolic repercussions. International Journal of Molecular Sciences. 2021;22: 2639.
Smekal A, Vaclavik J. Adipokines and cardiovascular disease: A comprehensive review. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia. 2017;161(1):31-40.
Senesi P, Luzi L, Terruzzi I. Adipokines, myokines, and cardiokines: The role of nutritional interventions. International Journal of Molecular Sciences. 2020; 21(21):8372.
Perrone MA, Aimo A, Bernardini S, et al. Inflammageing and cardiovascular system: Focus on cardiokines and cardiac-specific biomarkers. International Journal of Molecular Sciences. 2023;24:844.
Tofte N, Theilade S, Winther SA, et al. Comparison of natriuretic peptides as risk markers for all-cause mortality and cardiovascular and renal complications in individuals with Type 1 diabetes. Diabetes Care. 2021;44(2):595–603.
Baba M, Yoshida K, Ieda M. Clinical applications of natriuretic peptides in heart failure and atrial fibrillation. International Journal of Molecular Sciences. 2019;20(11):2824.
Horak M, Fairweather DL, Kokkonen P, et al. Follistatin-like 1 and its paralogs in heart development and cardiovascular disease. Heart Failure Reviews. 2022;27(6):2251-2265.
Lyngbakken MN, Myhre PL, Røsjø H, et al. Novel biomarkers of cardiovascular disease: Applications in clinical practice. Critical Reviews in Clinical Laboratory Sciences. 2019;56:33–60.
Yang C, Xin JY, Liu ZL, et al. Association between serum C1q tumor necrosis factor-related protein 9 and the clinical characteristics and prognosis of ischemic stroke. Neurology and Therapy. 2022;11:87–101.
Libby, P. Targeting inflammatory pathways in cardiovascular disease: The inflammasome, interleukin-1, interleukin-6 and beyond. Cells. 2021;10: 951.
Oliveira PGS, Schwed JF, Chiuso-Minicucci F, et al. Association between serum myostatin levels, hospital mortality, and muscle mass and strength following ST-elevation myocardial infarction. Heart, Lung Circulation. 2022;31:365–371.
Wollert KC, Kempf T, Wallentin L, Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clinical Chemistry. 2017;63:140-151.
Yang G, Hewei Q, Dandan L. ACSL4 mediates ferroptosis and its potential role in atherosclerotic cardiovascular disease. Chinese Journal of Tissue Engineering Research. 2025;29(6):1239-1247.
Myhre PL, Vaduganathan M, Solomon SD. Neprilysin and corin. It takes two to tango. JACC. Heart Failure. 2021;9(2):96-99.
Gommans DHF, Revuelta-Lopez E, Lupon J, et al. Soluble neprilysin and corin concentrations in relation to clinical outcome in chronic heart failure. JACC. Heart Failure. 2021;9(2):85 – 95.
Gladysheva IP, Sullivan RD, Reed GL, Neprilysin and corin in HF. Does combining 2 biomarkers double our insights? JACC. Heart Failure. 2021;9(5):406.
Guzy PM. Creatine phosphokinase-MB (CPK-MB) and the diagnosis of myocardial infarction. The Western Journal of Medicine. 1977;127(6):455.
Yaluri N, Stančáková Yaluri A, Žeňuch P, et al. Cardiac biomarkers and their role in identifying increased risk of cardiovascular complications in COVID-19 patients. Diagnostics (Basel). 2023;13(15):2508.
Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–810.
An W, Kang J-S, Wang Q, et al. Cardiac biomarkers and COVID-19: A systematic review and meta-analysis. Journal of Infection and Public Health. 2021;14:1191–1197.
Kumar N, Ahmad S, Mahto M, et al. Prognostic value of elevated cardiac and inflammatory biomarkers in patients with severe COVID-19: a single-center, retrospective study. Emergency and Critical Care Medicine. 2022;2(3):122-127.
Wang Z, Ma K, Zhu Y, et al. Predictive value of myocardial markers for early postoperative mortality in children with congenital heart disease. Pediatric Cardiology. 2024 Feb 16. doi: 10.1007/s00246-024-03404-0. Epub ahead of print.
Peetz D, Post F, Schinzel H, et al. Glycogen phosphorylase BB in acute coronary syndromes. Clinical Chemistry and Laboratory Medicine. 2005;43(12):1351–1358
Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clinical Chemistry. 2005;51(5):810–824
Krause E-G, Rabitzsch G, Noll F, et al. Glycogen phosphorylase isoenzyme BB in diagnosis of myocardial ischaemic injury and infarction. Molecular and Cellular Biochemistry. 1996;160(161):289–295.
Singh N, Rathore V, Mahat RK, et al. Glycogen phosphorylase BB: a more sensitive and specifc marker than other cardiac markers for early diagnosis of acute myocardial infarction. Indian Journal of Clinical Biochemistry. 2018;33(3):356–360.
Ghimire A, Giri S, Khanal N, et al. Diagnostic accuracy of glycogen phosphorylase BB for myocardial infarction: A systematic review and meta-analysis. Journal of Clinical Laboratory Analysis. 2022;36(5):e24368.
Yun DD, Alpert JS. Acute coronary syndromes. Cardiology. 1997;88(3):223–237.
He Z, Yan R, Liu J, et al. Lactate dehydrogenase and aspartate aminotransferase levels associated with the severity of COVID 19: A systematic review and meta analysis. Experimental and Therapeutic Medicine. 2023;25(5):221.
Topbas C, Swick A, Razavi M, et al. Measurement of lipoprotein-associated phospholipase A2 by use of 3 different methods: exploration of discordance between ELISA and activity assays. Clinical Chemistry. 2018;64(4):697–704.
Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. European Heart Journal. 2012;33(13):1635–1701.
Burke JE, Dennis EA. Phospholipase a2 biochemistry, Cardiovascular Drugs and Therapy. 2009;23(1):49–59.
De Stefano A, Mannucci L, Tamburi F, et al. Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases. International Journal of Immunopathology and Pharmacology. 2019;33, 2058738419827154.
Zhang S, Wang J, Chen S, et al. Serum levels of lipoprotein-associated phospholipase A2 are associated with coronary atherosclerotic plaque progression in diabetic and non-diabetic patients. BMC Cardiovascular Disorders. 2024;24(1):251.
Newby AC. Metalloproteinases promote plaque rupture and myocardial infarction: a persuasive concept waiting for clinical translation. Matrix Biology. 2015;44:157–166.
Wang L, Lü S, Zhang W, et al. Comparision of high sensitivity C-reactive protein and matrix metalloproteinase 9 in patients with unstable angina between with and without significant coronary artery plaques. Chinese Medical Journal. 2011;124(11):1657–1661.
Lenti M, Falcinelli E, Pompili M, et al. Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation. Correlation with ischemic events. Thrombosis and Haemostasis. 2014;111(6):1089–1101.
Peeters W, Moll FL, Vink A, et al. Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. European Heart Journal. 2011;32(18):2314–2325.
Goncalves I, Bengtsson E, Colhoun HM, et al. Elevated plasma levels of MMP-12 are associated with atherosclerotic burden and symptomatic cardiovascular disease in subjects with type 2 diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35(7):1723–1731.
Samah N, Ugusman A, Hamid AA, et al. Role of matrix metalloproteinase-2 in the development of atherosclerosis among patients with coronary artery disease. Mediators of Inflammation. 2023;2023:9715114.
Zhang R, Brennan M-L, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. Journal of American Medical Association. 2001;286(17):2136–2142.
Schindhelm RK, van der Zwan LP, Teerlink T, et al. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratifcation? Clinical Chemistry. 2009;55(8):1462–1470.
Khan AA, Alsahli MA, Rahmani AH. Myeloperoxidase as an active disease biomarker: recent biochemical and pathological perspectives. Medical Sciences (Basel). 2018;6(2):3.
Vanek T, Kohli A. Biochemistry, Myoglobin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.
Kottwitz J, Bruno KA, Berg J, et al. Myoglobin for detection of high-risk patients with acute myocarditis. Journal of Cardiovascular Translational Research. 2020;13:853–863.
Cohen JC, Boerwinkle E, Mosley TH, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine. 2006;354(12),1264-1272.
Cho KH, Hong YJ. Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives. The Korean Journal of Internal Medicine. 2020;35(5): 1045–1058.
Hosseini K, Soleimani H, Maleki S, et al. Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis. BMC Cardiovascular Disorders. 2024;24(1):395.
Rosengren B, Peilot H, Umaerus M, et al. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a western diet. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26 (7):1579–1585.
Henderson WR Jr, Chi EY, Bollinger JG, et al. Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. The Journal of Experimental Medicine. 2007;204(4):865–877.
Feng Y, He LQ. Soluble ST2: A novel biomarker for diagnosis and prognosis of cardiovascular disease. Current Medical Science. 2024;44(4):669-679.
Sulu A, Uner G, Kosger P, et al. Does the ST2 level in pediatric heart failure patients correlate with cardiovascular events and mortality? Children (Basel). 2024;11(6):718.
Lai J, Huang C, Li B, et al. Soluble ST2 as a possible biomarker for inflammation in patients with acute heart failure. Journal of Cardiovascular Medicine (Hagerstown). 2024;25(3):186-192.
Patibandla S, Gupta K, Alsayouri K. Cardiac Enzymes. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 31424800.
Welsh P, Preiss D, Hayward C, et al. Cardiac troponin T and Troponin I in the general population. Circulation. 2019;139:2754–2764
Guo L, Zhou L, Wei P, et al. Emerging roles of UDP-GalNAc polypeptide N acetylgalactosaminyltransferases in cardiovascular disease. Aging and Disease. 2025;16(1):1-11.
Nishikimi T, Kato J. Cardiac peptides—Current physiology, pathophysiology, biochemistry, molecular biology, and clinical application. Biology. 2022;11:330.
Fischer JP, Els-Heindl S, Beck-Sickinger AG. Adrenomedullin - Current perspective on a peptide hormone with significant therapeutic potential. Peptides. 2020;131:170347.
Nishikimi T, Matsuoka H. Cardiac adrenomedullin: Its role in cardiac hypertrophy and heart failure. Current Medicinal Chemistry. Cardiovascular and Hematological Agents. 2005;3:231–242.
Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation. 2000;101:498–503.
Schaefer M, Stein A, Ruf B, et al. Bioactive adrenomedullin (bio-ADM) is associated with endothelial dysfunction in infants and children with complex congenital heart disease undergoing open-heart surgery on cardiopulmonary bypass. Clinical Chemistry and Laboratory Medicine. 2023;62(3):551-561.
Lyu JX, Guo DD, Song YC, et al. Circulating myokines as novel biomarkers for cardiovascular diseases. Reviews in Cardiovascular Medicine. 2024;25(2):56.
Yeves AM, Coto JG, Cavalli F, et al. Does apelin mediate the cardioprotective effects of IGF-1? Journal of Molecular and Cellular Cardiology. 2022;173(Supplement):131.
Rafaqat S. Adipokines and their role in heart failure: A literature review. The Journal of Innovations in Cardiac Rhythm Management. 2023;14(11):5657-5669.
Chandrasekaran B, Dar O, McDonagh T. The role of apelin in cardiovascular function and heart failure. European Journal of Heart Failure. 2008;10(8):725–732.
El Amrousy D, El-Mahdy H. Prognostic value of serum apelin level in children with heart failure secondary to congenital heart disease. Pediatric Cardiology. 2018;39:1188–1193
Wysocka MB, Pietraszek-Gremplewicz K, Nowak D. The role of apelin in cardiovascular diseases, obesity and cancer. Frontiers in Physiology. 2018;9:557.
Adusu-Donkor L, Ofori EK, Kotey FCN, et al. Blood C-peptide concentration as a proxy marker of cardiovascular disease: An observational cross-sectional study. Health Science Reports. 2023;6(9):e1535.
Goetze JP, Rehfeld JF, Alehagen U. Cholecystokinin in plasma predicts cardiovascular mortality in elderly females. International Journal of Cardiology. 2016;209:37-41.
Ruan H, Mandla R, Ravi N, et al. Cholecystokinin-A signaling regulates automaticity of pacemaker cardiomyocytes. Frontiers in Physiology. 2023;14:1284673.
Mu D, Cheng J, Qiu L, et al. Copeptin as a diagnostic and prognostic biomarker in cardiovascular diseases. Frontiers in Cardiovascular Medicine. 2022;9:901990.
Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. Journal of the American College of Cardiology. 2009;54(1):60–68.
Kassem M, Ayala PL, Andric-Cancarevic T, et al. Copeptin for the differentiation of type 1 versus type 2 myocardial infarction or myocardial injury. Inernational Journal of Cardiology. 2024;403:131879.
Lin L-Y, Chang TT, Leu HB, et al. Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease. Clinical Research in Cardiology. 2024 May 13. doi: 10.1007/s00392-024-02458-7. Epub ahead of print.
Dmour BA, Costache AD, Dmour A, et al. Could endothelin-1 be a promising neurohormonal biomarker in acute heart failure? Diagnostics (Basel). 2023;13(13):2277.
Fu J, Tang Y, Zhang Z, et al. Gastrin exerts a protective effect against myocardial infarction via promoting angiogenesis. Molecular Medicine (Cambridge, Mass.) 2021;27:90.
Fang D, Li Y, He B, et al. Gastrin attenuates sepsis-induced myocardial dysfunction by down-regulation of TLR4 expression in macrophages. Acta Pharmaceutica Sinica B. 2023;13(9):3756-3769.
Tokudome T, Kangawa K. Physiological significance of ghrelin in the cardiovascular system. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences. 2019;95:459–467
Gruzdeva OV, Borodkina DA, Belik EV, et al. Ghrelin physiology and pathophysiology: focus on the cardiovascular system. Kardiologiya 2019;59:60–67
Hosoda H. Effect of ghrelin on the cardiovascular system. Biology. 2022;11:1190.
Kok CY, Ghossein G, Igoor S, et al. Ghrelin mediated cardioprotection using in vitro models of oxidative stress. Gene Therapy. 2024;31(3-4):165-174.
Yuan MJ, Li W, Zhong P. Research progress of ghrelin on cardiovascular disease. Bioscience Reports. 2021;41(1): BSR20203387.
Dziedzic M, Józefczuk E, Guzik TJ, et al. Interplay between plasma glycine and branched-chain amino acids contributes to the development of hypertension and coronary heart disease. Hypertension. 2024; 81(6):1320-1331.
Alcidi G, Goffredo G, Correale M, et al. Brain natriuretic peptide biomarkers in current clinical and therapeutic scenarios of heart failure. Journal of Clinical Medicine. 2022;11(11):3192.
110. Gaborit FS, Kistorp C, Kümler T, et al. Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study. Biomarkers. 2020;25(3):248-259.
Cui K, Huang W, Fan J, et al. Midregional pro-atrial natriureticpeptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction. Medicine. 2018;97(36):e12277.
Gohar A, Rutten FH, den Ruijter H, et al. Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure. European Journal of Heart Failure. 2019;21(10):1219-1227.
Wild PS, Schnabel RB, Lubos E, et al. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the Athero Gene Study. Clinical Chemistry. 2012;58(1):226–236.
Francis GS, Felker GM, Tang WW. A test in context: critical evaluation of natriuretic peptide testing in heart failure. Journal of the American College of Cardiology. 2016;67(3):330–337.
Dres M, Hausfater P, Foissac F, et al. Mid-regional proadrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study. International Journal of Chronic Obstructive Pulmonary Disease. 2017;12:1047
Lopes D, Falcao LM. Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis. Revista Portuguesa de Cardiologia. 2017;36(6):465–472
Pervez MO, Winther JA, Brynildsen J, et al. Prognostic and diagnostic signifcance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study. Biomarkers. 2018;23(7):654–663.
Goudot FX, Paugam M, Bendaoud N, et al. Measurement of natriuretic peptides in patients with suspected heart failure to prevent overuse of echocardiography - a pilot study. Clinical Laboratory. 2024;70(7).
Velasquez MT, Ramezani A, Manal A, et al. Trimethylamine N-Oxide: The good, the bad and the unknown. Toxins (Basel). 2016;8(11):326.
Bao M, Li H, Li J. Circulating trimethylamine N-oxide is correlated with high coronary artery atherosclerotic burden in individuals with newly diagnosed coronary heart disease. BMC Cardiovascular Disorders. 2024;24(1):265.
Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy. 2022;7:48.
Al Shaer D, Al Musaimi O, Albericio F, et al. 2021 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel). 2022; 15:222.
de la Torre BG, Albericio F. Peptide therapeutics 2.0. Molecules 2020;25:2293.
Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology. 2021;12:627533.
Ross A, Sauce-Guevara MA, Alarcon EI, et al. Peptide biomaterials for tissue regeneration. Frontiers in Bioengineering and Biotechnology. 2022;10:893936.
Recio C, Maione F, Iqbal AJ, et al. The potential therapeutic application of peptides and peptidomimetics in cardiovascular disease. Frontiers in Pharmacology. 2017;7:526.
Sikiric P, Udovicic M, Barisic I, et al. Stable gastric pentadecapeptide BPC 157 as useful cytoprotective peptide therapy in the heart disturbances, myocardial infarction, heart failure, pulmonary hypertension, arrhythmias, and thrombosis presentation. Biomedicines. 2022;10(11):2696.
Wang F, He Y, Yao N, et al. Thymosin β4 protects against cardiac damage and subsequent cardiac fibrosis in mice with myocardial infarction. Cardiovascular Therapeutics. 2022;2022:1308651.
Gava FN, da Silva AA, Dai X, et al. Restoration of cardiac function after myocardial infarction by long-term activation of the CNS leptin-melanocortin system. JACC. Basic to Translational Science. 2021;6(1):55-70.
Schally AV, Zhang X, Cai R, et al. Actions and potential therapeutic applications of growth hormone-releasing hormone agonists. Endocrinology. 2019;160(7):1600-1612.
Jankowska EA, Ponikowski P. Acyl-ghrelin therapy for heart failure: already a novel inotrope or even more? European Heart Journal. 2023;44(22):2026-2028.
Lund LH, Hage C, Pironti G, et al. Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization. European Heart Journal. 2023;44(22):2009-2025.
Bohn MK, Steele S, Hall A, et al. Cardiac biomarkers in pediatrics: An undervalued resource. Clinical Chemistry. 2021;67(7):947-958.
